Name: Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed
Brand: reuters.com
SKU: reuters-com-2526
Availability: OnlineOnly

critic

Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed

preview

By , Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate U.S. government trial. That study showed a trend toward better survival for remdesivir but the difference was not statistically significant.In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity.Gilead’s late-stage study evaluated the safety and efficacy of five-day and 10-day dosing durations of remdesivir in hospitalized patients. The study did not have a placebo comparison.Dr. Susan Olender from Columbia University Irving Medical Center said in the Gilead statement that the analysis draws from a real-world setting and serves as an important adjunct to clinical trial data even as it is not as vigorous as a randomized controlled trial.However, Dr. Walid Gellad, a professor at University of Pittsburgh’s medical school, called it “a joke” to compare clinical trial data with observational data and conclude anything definitive about mortality.“The mortality in the remdesivir trials has generally been lower for both control and intervention groups than other trials and other real world cohorts I’ve seen,” Gellad said in an email.“The real world patients are taken care of at different hospitals than those in the trial and potentially different adjunct treatments. They’re different.”Findings from the analysis showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.The U.S. government trial in April showed that patients given remdesivir recovered 31% faster than those given a placebo.Gilead’s shares rose 2% to $76.27 in afternoon trading.Editing by Anil D’Silva, Maju Samuel and Lewis KrauskopfOur Standards:

By , Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate U.S. government trial. That study showed a trend toward better survival for remdesivir but the difference was not statistically significant.In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity.Gilead’s late-stage study...

public

Ankur Banerjee

I write for Reuters. My articles can be found here: http://blogs.reuters.com/michael-erman/

Michael Erman

Top and breaking news, pictures and videos from Reuters. For more breaking business news, follow @ReutersBiz.

reuters.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS